Endocrine therapy for prostate cancer.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prostate cancer consists of epithelial and stromal elements that are heterogeneous with regard to androgen dependence. Nearly 80% of patients with symptomatic metastatic prostate cancer obtain prompt objective and subjective response to androgen deprivation. Surgical castration remains an effective form of therapy, has low morbidity, and obviates compliance problems with medical regimens. New LH-RH analogs offer complete medical androgen deprivation, appear as effective as estrogen therapy at 2-year follow-up, and have significantly lower cardiovascular side effects. Thus, LH-RH analogs may replace estrogen therapy for the medical management of metastatic prostate cancer. Androgen deprivation therapy has not been proved to prolong the survival of patients with prostate cancer. The optimal timing for initiation of endocrine therapy in these patients remains controversial. Techniques for predicting androgen dependence of prostate cancer are still evolving and are not yet applicable on a widespread clinical basis.

Original languageEnglish (US)
Pages (from-to)101-129
Number of pages29
JournalSpecial topics in endocrinology and metabolism
Volume7
StatePublished - 1985

Fingerprint

Androgens
Prostatic Neoplasms
Gonadotropin-Releasing Hormone
Estrogens
Therapeutics
Castration
Compliance
Morbidity
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Endocrine therapy for prostate cancer. / Sagalowsky, Arthur I.

In: Special topics in endocrinology and metabolism, Vol. 7, 1985, p. 101-129.

Research output: Contribution to journalArticle

@article{7be661b7d1fc4270852d848d50f8c6e0,
title = "Endocrine therapy for prostate cancer.",
abstract = "Prostate cancer consists of epithelial and stromal elements that are heterogeneous with regard to androgen dependence. Nearly 80{\%} of patients with symptomatic metastatic prostate cancer obtain prompt objective and subjective response to androgen deprivation. Surgical castration remains an effective form of therapy, has low morbidity, and obviates compliance problems with medical regimens. New LH-RH analogs offer complete medical androgen deprivation, appear as effective as estrogen therapy at 2-year follow-up, and have significantly lower cardiovascular side effects. Thus, LH-RH analogs may replace estrogen therapy for the medical management of metastatic prostate cancer. Androgen deprivation therapy has not been proved to prolong the survival of patients with prostate cancer. The optimal timing for initiation of endocrine therapy in these patients remains controversial. Techniques for predicting androgen dependence of prostate cancer are still evolving and are not yet applicable on a widespread clinical basis.",
author = "Sagalowsky, {Arthur I}",
year = "1985",
language = "English (US)",
volume = "7",
pages = "101--129",
journal = "Special topics in endocrinology and metabolism",
issn = "0193-0982",

}

TY - JOUR

T1 - Endocrine therapy for prostate cancer.

AU - Sagalowsky, Arthur I

PY - 1985

Y1 - 1985

N2 - Prostate cancer consists of epithelial and stromal elements that are heterogeneous with regard to androgen dependence. Nearly 80% of patients with symptomatic metastatic prostate cancer obtain prompt objective and subjective response to androgen deprivation. Surgical castration remains an effective form of therapy, has low morbidity, and obviates compliance problems with medical regimens. New LH-RH analogs offer complete medical androgen deprivation, appear as effective as estrogen therapy at 2-year follow-up, and have significantly lower cardiovascular side effects. Thus, LH-RH analogs may replace estrogen therapy for the medical management of metastatic prostate cancer. Androgen deprivation therapy has not been proved to prolong the survival of patients with prostate cancer. The optimal timing for initiation of endocrine therapy in these patients remains controversial. Techniques for predicting androgen dependence of prostate cancer are still evolving and are not yet applicable on a widespread clinical basis.

AB - Prostate cancer consists of epithelial and stromal elements that are heterogeneous with regard to androgen dependence. Nearly 80% of patients with symptomatic metastatic prostate cancer obtain prompt objective and subjective response to androgen deprivation. Surgical castration remains an effective form of therapy, has low morbidity, and obviates compliance problems with medical regimens. New LH-RH analogs offer complete medical androgen deprivation, appear as effective as estrogen therapy at 2-year follow-up, and have significantly lower cardiovascular side effects. Thus, LH-RH analogs may replace estrogen therapy for the medical management of metastatic prostate cancer. Androgen deprivation therapy has not been proved to prolong the survival of patients with prostate cancer. The optimal timing for initiation of endocrine therapy in these patients remains controversial. Techniques for predicting androgen dependence of prostate cancer are still evolving and are not yet applicable on a widespread clinical basis.

UR - http://www.scopus.com/inward/record.url?scp=0022293269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022293269&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 101

EP - 129

JO - Special topics in endocrinology and metabolism

JF - Special topics in endocrinology and metabolism

SN - 0193-0982

ER -